-
公开(公告)号：AU3067499A
公开(公告)日：1999-10-18
申请号：AU3067499
申请日：1999-03-11
Applicant: ABBOTT LAB
Inventor： SAUER DARYL R , HAVIV FORTUNA , RANDOLPH JOHN , MORT NICHOLAS A , DALTON CHRISTOPHER R , BRUNCKO MILAN , KAMINSKI MICHELE A , CRAWFORD BRADLEY W , FREY LISA MARIE , GREER JONATHON
IPC: A61K31/7042 , A61K31/7048 , A61K31/7056 , A61P5/24 , A61P13/08 , A61P15/00 , A61P35/00 , A61P43/00 , C07H17/08
Abstract: Disclosed are 3'-N-desmethyl-3'-N-substituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.
-
公开(公告)号：CA2136078A1
公开(公告)日：1994-06-23
申请号：CA2136078
申请日：1993-11-30
Applicant: ABBOTT LAB
Inventor： GREER JONATHAN , HAVIV FORTUNA , FITZPATRICK TIMOTHY D , SWENSON ROLF E , NICHOLS CHARLES J , MORT NICHOLAS A
Abstract: 2136078 9413313 PCTABS00032 The present invention provides a class of decapeptide compounds which are potent antagonists of LHRH activity and which have the structure A1-D2-E3-G4-J5-L6-M7-Q8-R9-T10. The compounds of the percent invention are characterized by having an .OMEGA.-amino-functionalized side chain on the D-aminoacyl residue at position 6. The .OMEGA.-amino group of this side chain is further derivatized by the attachment of an extending group which likewise has a terminal amino group which is capped by an acyl group.
-
公开(公告)号：NO903454A
公开(公告)日：1991-02-08
申请号：NO903454
申请日：1990-08-06
Applicant: ABBOTT LAB
Inventor： HAVIV FORTUNA , GREER JONATHAN , PALABRICA CHRISTOPHER A , FITZPATRICK TIMOTHY D
-
公开(公告)号：GB2116964B
公开(公告)日：1985-07-17
申请号：GB8304419
申请日：1982-09-20
Applicant: ABBOTT LAB
Inventor： HAVIV FORTUNA , RATAJCZYK JAMES DANIEL , FISCHER FRANCIS ELMER
IPC: A01N43/36 , A01N43/76 , A01N43/78 , A01N43/80 , A61K31/40 , A61K31/42 , A61K31/425 , C07D209/40 , C07D235/30 , C07D263/00 , C07D263/58 , C07D277/82 , C07D265/30
Abstract: Described are compounds of the formula wherein R is hydrogen or loweralkyl, X, Y and W independently of one another denote hydrogen, halogen, loweralkyl, nitro, amino, amido, loweralkoxy, hydroxy, nitrile, methylsulfone, methylsulfoxide, methylmercapto, or trifluoromethyl; Z is oxygen, sulfur or -CH2; n and m are each an integer from 0 to 6 inclusive, or pharmaceutically acceptable salts thereof. The compounds are effective as anti-inflammatory agents.
-
公开(公告)号：DE3249054T1
公开(公告)日：1983-11-17
申请号：DE3249054
申请日：1982-09-20
Applicant: ABBOTT LAB
Inventor： HAVIV FORTUNA , RATAJCZYK JAMES DANIEL , FISCHER FRANCIS ELMER
IPC: A01N43/36 , A01N43/76 , A01N43/78 , A01N43/80 , A61K31/40 , A61K31/42 , A61K31/425 , C07D209/40 , C07D235/30 , C07D263/00 , C07D263/58 , C07D277/82
Abstract: Described are compounds of the formula wherein R is hydrogen or loweralkyl, X, Y and W independently of one another denote hydrogen, halogen, loweralkyl, nitro, amino, amido, loweralkoxy, hydroxy, nitrile, methylsulfone, methylsulfoxide, methylmercapto, or trifluoromethyl; Z is oxygen, sulfur or -CH2; n and m are each an integer from 0 to 6 inclusive, or pharmaceutically acceptable salts thereof. The compounds are effective as anti-inflammatory agents.
-
Patent Agency Ranking
公开(公告)号：CY1109118T1
公开(公告)日：2014-07-02
申请号：CY081100792
申请日：2008-07-29
Applicant: ABBOTT LAB
Inventor： HENKIN JACK , HAVIV FORTUNA , BRADLEY MICHAEL F , KALVIN DOUGLAS M , SCHNEIDER ANDREW J
IPC: A61K38/00 , C07K14/78 , A61K38/39 , A61P9/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P31/04 , A61P35/00 , C07K7/06 , G01N33/68
Abstract: Πεπτίδιαπουέχουντονχημικότύπο: Α0-Α1-Α2-Α3-Α4-Α5-Α6-Α7-Α8-Α9-Α10 στονοποίοντοΑ0 επιλέγεταιαπόυδρογόνοή μιαομάδαακυλίου· τοΑιοείναιμιαυδροξυομάδαή ένααμίδιοαμινοξέως· καιτα: Α1, Α2, Α3, Α4, Α5, Α6, Α7, Α8 καιΑ9 είναικατάλοιπααμινοακυλίουωςορίζεταισύμφωναμετοπαρόν.
-
公开(公告)号：AT513846T
公开(公告)日：2011-07-15
申请号：AT10153271
申请日：2002-10-30
Applicant: ABBOTT LAB
Inventor： HAVIV FORTUNA , BRADLEY MICHAEL
IPC: A61K38/00 , C07K7/06 , A61K38/08 , A61P1/04 , A61P3/10 , A61P7/04 , A61P9/00 , A61P9/10 , A61P9/14 , A61P15/18 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P39/00 , A61P43/00
Abstract: Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
-
48.发明专利
公开(公告)号：SK286554B6
公开(公告)日：2008-12-05
申请号：SK17632000
申请日：1999-05-21
Applicant: ABBOTT LAB
Inventor： HENKIN JACK , HAVIV FORTUNA , BRADLEY MICHAEL F , KALVIN DOUGLAS M , SCHNEIDER ANDREW J
IPC: A61K38/00 , C07K14/00 , A61P9/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P31/04 , A61P35/00 , C07K7/06 , C07K14/78 , G01N33/00
Abstract: The present invention relates to peptides of formula: A0-A1-A2-A3-A4-A5-A6-A7-A8--A9-A10, wherein A1 is sarcosyl, A2 is glycyl, A3 is valyl, A7 is isoleucyl, A8 is arginyl, A9 is prolyl, A4, A5 and A6 are amino acyl residues, A10 is selected from hydroxyl, azaglycylamide, D-alanylamide, sarcosylamide, serylamide, D-serylamide, NH-(CH2)s -C(R2)HR3 and -NH-R4 and pharmaceutically acceptable salts, esters or solvates thereof. The present invention further relates to pharmaceutical compositions containing the same and their medical use.
-
公开(公告)号：ES2256071T3
公开(公告)日：2006-07-16
申请号：ES00982219
申请日：2000-11-22
Applicant: ABBOTT LAB
Inventor： HAVIV FORTUNA , HENKIN JACK , BRADLEY MICHAEL F , KALVIN DOUGLAS M , SCHNEIDER ANDREW J
IPC: A61K38/00 , A61P9/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P35/00 , C07K1/22 , C07K7/06 , C07K14/705 , C07K14/78 , A61K38/39
Abstract: Un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo en la que Xaa1 se selecciona entre el grupo compuesto por: acetilo, y 6-metilnicotinilo; Xaa2 es sarcosilo; Xaa3 es glicilo; Xaa4 se selecciona entre el grupo compuesto por aloisoleucilo alilglicil o, 2-aminobutirilo, (1R, 4S)-1-aminociclopent-2-eno-4-carbonilo, 3-(5-bromotien-2-il)alanilo, 3-(3-clorofenil)alanilo, 3-(4-clorofenil)alanilo, 3-(3-cianofenil)alanilo, cisteinil(S-etilo), cisteinil(S-metilo), 2, 3-diaminopropionilo; 2, 4-diaminobutanoílo, 3-(3, 4-dimetoxifenil)alanilo, 3-(3- fluorofenil)alanil o, 3-(4-fluorofenil)alanilo, homofenilalanilo, homoserilo, lisil(N-épsilon-acetilo), metionil(sulfon a), metionil(sulfóxido), 3-(4-metilfenil)alanilo, 3-(naft-1-il)alanilo, 3-(naft-2-il)alanilo, ornitilo, fenilglicilo, 3-(3-piridil)alanilo, seril(O-bencilo), estirilalanilo, 1, 2, 3, 4-tetrahidroisoquinolin-3-carbonilo, 3-(tiazolil)alanilo, 3-(tien-2-il)alanilo, y D-3-(tien-2-il)alanilo; Xaa5 se selecciona entre elgrupo compuesto por isoleucilo, D-isoleucilo, y D-leucilo; Xaa6 se selecciona entre el grupo compuesto por serilo, y treonilo; Xaa7 se selecciona entre el grupo compuesto por glutaminilo, norvalilo, y serilo; Xaa8 es isoleucilo; Xaa9 es arginilo; Xaa10 es prolilo; y Xaa11 se selecciona entre el grupo compuesto por D-alanilamida, y NH-etilo.
-
公开(公告)号：SI1066304T1
公开(公告)日：2005-10-31
申请号：SI9930779
申请日：1999-03-11
Applicant: ABBOTT LAB
-
-
-
-
-
-
-
-
-
Search Results
186
records
(took 0.019 seconds)
